[4-(4-Methoxy-benzyloxy)-phenyl]-methanol | 77182-74-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(4-Methoxy-benzyloxy)-phenyl]-methanol
• 英文别名: 4-(4'-methoxybenzyloxy)benzyl alcohol；4-(4'-methoxybenzyloxy)benzylalcohol；4-[(4-methoxybenzyl)oxy]benzyl alcohol；4-[(4-Methoxybenzyl)oxy]benzylalcohol；[4-[(4-methoxyphenyl)methoxy]phenyl]methanol
• CAS: 77182-74-2
• 化学式: C₁₅H₁₆O₃
• mdl: MFCD11524412
• 分子量: 244.29
• InChiKey: CPNBUCKGQNVQFY-UHFFFAOYSA-N

物化性质

• 熔点：
  115-117 °C
• 沸点：
  409.9±30.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-(4-Methoxy-benzyloxy)-phenyl]-methanol 在 lithium hydroxide 、 caesium carbonate 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙腈 为溶剂， 生成 {7-[4-(4-Methoxy-benzyloxy)-benzylsulfanyl]-indan-4-yloxy}-acetic acid
  参考文献：
  名称：

  Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists

  摘要：

  A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.046
• 作为产物：
  描述：

  4-[(4-甲氧基苯基)甲氧基]苯甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以83 mg的产率得到[4-(4-Methoxy-benzyloxy)-phenyl]-methanol
  参考文献：
  名称：

  Studies on the constituents of Gastrodia elata Blume.

  摘要：

  从天麻（Gastrodia elata BLUME，兰科）的块茎中分离得到一个新化合物，命名为天麻苷，其结构被阐明为双（4-羟基苄基）醚单-β-D-吡喃葡糖苷（6）。同时分离得到的还有4-羟基苯甲醛（1）、4-羟基苄醇（2）、4-羟基苄基甲醚（3，可能为人为产物）、4-（4'-羟基苄氧基）苄基甲醚（4）、双（4-羟基苄基）醚（5）、4-（β-D-吡喃葡糖氧基）苄醇（7）和三[4-（β-D-吡喃葡糖氧基）苄基]柠檬酸酯（穗花杉双黄酮，8）。这是首次从天然来源中分离出化合物4和5。

  DOI：

  10.1248/cpb.29.55

文献信息

• Melanin concentrating hormone antagonist
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07115750B1

  公开（公告）日：2006-10-03

  A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R1 and R2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.

  一种黑色素浓缩激素拮抗剂，包括以下式的化合物： 其中Ar1是可能具有取代基团的环状基团； X是具有1到6个原子的主链的间隔物； Y是键或具有1到6个原子的主链的间隔物； Ar是可能与4到8个成员的非芳香环融合的单环芳香环，并且可能具有进一步的取代基团； R1和R2分别是氢原子或可能具有取代基团的碳氢基团；R1和R2，连同相邻的氮原子，可能形成可能具有取代基团的含氮杂环；R2可能与Ar一起形成螺环；或者R2，连同相邻的氮原子和Y，可能形成可能具有取代基团的含氮杂环；或其盐； 该化合物可用作预防或治疗肥胖等疾病的药剂。
• Compounds that modulate PPAR activity and methods for their preparation
  申请人：——

  公开号：US20030225158A1

  公开（公告）日：2003-12-04

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

  该发明揭示了可以改变PPAR活性的化合物。该发明还揭示了这些化合物的药用可接受盐、含有这些化合物或其盐的药用可接受组合物，以及将它们用作治疗或预防哺乳动物的失脂血症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉粥样硬化、高甘油三酯血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。
• Breaking the dichotomy of reactivity vs. chemoselectivity in catalytic S_N1 reactions of alcohols
  作者：Malik Hellal、Florian C. Falk、Eléna Wolf、Marian Dryzhakov、Joseph Moran

  DOI：10.1039/c4ob01265h

  日期：——

  B(C₆F₅)₃ possesses a different reactivity/chemoselectivity profile than traditional Lewis and Brønsted acids and is effective at enabling catalytic S_N1 reactions of alcohols in the presence of acid sensitive groups without compromising reaction rates, substrate scope or catalyst loadings.

  B(C6F5)3具有与传统的Lewis酸和Brønsted酸不同的反应性/化学选择性特征，并且在存在酸敏感基团的情况下，能够有效地促进醇的催化SN1反应，而不会影响反应速率、底物范围或催化剂负荷。
• COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION
  申请人：Auerbach J. Bruce

  公开号：US20050153996A1

  公开（公告）日：2005-07-14

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

  本发明揭示了能够改变PPAR活性的化合物。本发明还揭示了这些化合物的药学上可接受的盐，包含这些化合物或其盐的药学上可接受的组合物，以及将它们用作治疗或预防哺乳动物的失脂症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉硬化、高三酰甘油血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。
• Amplifying the Negative Solvatochromism of Pyridinium Phenolates via Fluorene Conjugation
  作者：Irina Zharinova、Nicolau Saker Neto、Wallace W. H. Wong

  DOI：10.1021/acs.chemmater.3c02063

  日期：2024.1.9

  negative solvatochromic behavior, with a smooth bathochromic shift observed upon decreasing the solvent polarity. Notably, examples FL1a and FL3 exhibited wide solvatochromic shifts of 235 and 297 nm, respectively, as the solvent polarity gradually lowered from polar water to less polar pyridine. Remarkably, the magnitude of the shift for FL3 was even greater than that of Reichardt’s dye (253 nm) in

  报道了携带由芴间隔基分隔的供体酚盐基团和受体吡啶基部分的新发色团。通过使用 Suzuki-Miyaura 或 Horner-Wadsworth-Emmons 耦合引入额外的苯环和一个或两个乙烯基连接体，可以实现系统的逐步伸长。这些供体-桥-受体分子的两性离子形式FL1 – FL5通过随后的N-甲基化和去质子化反应生成，导致吸光度最大值发生大的红移。紫外可见吸光度研究还揭示了负溶剂化变色行为，在降低溶剂极性时观察到平滑的红移。值得注意的是，当溶剂极性从极性水逐渐降低到极性较小的吡啶时，实施例FL1a和FL3分别表现出235和297nm的宽溶剂化变色位移。值得注意的是，在相同的溶剂范围内， FL3的位移幅度甚至大于 Reichardt 染料 (253 nm)，而 Reichardt 染料是已报道的性能最好的溶剂化变色染料之一。除了延长缀合之外，芴部分还允许进行简单的侧链工程，使这些溶剂化变色染